Program
RNK08954
A development code. Also written as “IN10018 in combination with RNK08954”.
Its studies are led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ranok Therapeutics (Hangzhou) | 22 open or running | phase 2since Nov 30, 2025 | Nov 30, 2025 | Nov 30, 2026phase 2 · NCT07303465 |
| InxMed (Shanghai) | 11 open or running | phase 2since Feb 13, 2026 | Feb 13, 2026 | Feb 28, 2031phase 2 · NCT07441174 |
| Ranok Therapuetics | 11 open or running | phase 2since Aug 31, 2026 | Aug 31, 2026 | Aug 31, 2028phase 2 · NCT07848893 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2025First study: phase 2 study in KRAS G12D MutationsNew to Ranok Therapeutics (Hangzhou)Ranok Therapeutics (Hangzhou) · NCT07303465 · 60 planned · China
- Dec 31, 2025Phase 1 study in Food EffectRanok Therapeutics (Hangzhou) · NCT07334262 · 24 planned · China
- Feb 13, 2026InxMed (Shanghai)'s first study: phase 2 study in Solid Tumor CancerNew to InxMed (Shanghai)InxMed (Shanghai) · NCT07441174 · 92 planned · China
- Aug 31, 2026Ranok Therapuetics's first study: phase 2 study in Advanced Gynecologic MalignanciesNew to Ranok TherapueticsRanok Therapuetics · NCT07848893 · 120 planned · China
Ahead
- Nov 30, 2026Primary completion: phase 2 study in KRAS G12D MutationsRanok Therapeutics (Hangzhou) · NCT07303465
- Dec 1, 2026Primary completion: phase 1 study in Food EffectRanok Therapeutics (Hangzhou) · NCT07334262
- Aug 31, 2028Primary completion: phase 2 study in Advanced Gynecologic MalignanciesRanok Therapuetics · NCT07848893
- Feb 28, 2031Primary completion: phase 2 study in Solid Tumor CancerInxMed (Shanghai) · NCT07441174
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07848893Advanced Gynecologic Malignancies · China | 2 | Not yet recruiting | Ranok Therapuetics | Aug 31, 2028 | 120 |
| NCT07441174Solid Tumor Cancer · China | 2 | Recruiting | InxMed (Shanghai) | Feb 28, 2031 | 92 |
| NCT07334262Food Effect · China | 1 | Not yet recruiting | Ranok Therapeutics (Hangzhou) | Dec 1, 2026 | 24 |
| NCT07303465KRAS G12D Mutations · China | 2 | Recruiting | Ranok Therapeutics (Hangzhou) | Nov 30, 2026 | 60 |
How it is read
Names in the registry
- “RNK08954”, 3 entries
- “IN10018 in combination with RNK08954”, 1 entry
Codes read as this program: RNK08954.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.